CHILDRENS CANCER GROUP

匹兹堡儿童癌症小组的主要目标是 to improve改善the outcome结果for children儿童with cancer癌症.这一目标 通过以下方式实现： 1.为患癌症的儿童提供机会， 参与CCG协议。 2.为CCG研究方案提供患者。 3.为这些研究提供患者的生物标本 协议. 4.为结果分析提供准确的患者数据。 5.提供熟练的医疗专业人员来计划、实施和评估 研究。 6.开发和测试新的想法与当地的研究项目。 7.在最低限度内有效地管理和开展这些研究 成本 这项研究是在匹兹堡儿童医院（CHP）进行的， 一家拥有235张床位的非盈利医院， 为四到五百万的人口。CHP与 匹兹堡大学医学院，并担任其系 儿科卫生防护中心也是匹兹堡癌症协会的正式成员 该研究所是NIH指定的综合癌症中心， 自1961年以来一直是CCG成员。在过去的一年里，一个完全翻新， 专门的肿瘤病房和新的CCG批准的骨髓移植 (BMT)我们的研究项目已经启动，以提高我们的研究能力。 我们的多学科儿科肿瘤学/BMT团队已扩展至10个 肿瘤学家，包括外科医生（包括神经和骨科）， 放射肿瘤学家，诊断放射学家，儿科病理学家， 血液病理学家，细胞遗传学家，神经学家，流行病学家， 心脏病专家、心理学家和完整的支持团队（护理、数据 管理人员、社会服务机构、标本协调员等）。与开口 新的CHP Rangos研究大楼和建立三个新的 教师与独立的资金，我们增加了我们的实验室 研究，并预计基础研究的贡献， CCG。随着更多的调查人员，我们也预计最大 参与CCG。我们希望增加患者入组， 治疗学、生物学和流行病学研究。有139名患者 1992年期间入组研究（治疗、特殊和流行病学）， 我们预计在未来几年内，研究人数甚至会更高，因为我们 在过去的一年里，该中心被批准为第一阶段和BMT中心。我们 还计划在CCG中发挥更大的科学和行政作用 最近我们的员工增加了此外，我们还有当地 独立的癌症研究项目正在进行中，我们希望这将有助于 我们的病人和CCG这些非CCG临床和实验室癌症 项目包括但不限于： 急性白血病细胞;重组生长因子;神经母细胞瘤治疗 去铁胺;描绘信号转导介导的机制 原癌基因信号转导的研究 包括反义分子的抗增殖作用。

The major objective of the Childrens Cancer Group (CCG) in Pittsburgh is to improve the outcome for children with cancer. This objective is achieved by: 1. Providing children with cancer the opportunity to benefit from participation in CCG protocols. 2. Providing patients for CCG research protocols. 3. Providing biologic specimens from patients for these research protocols. 4. Providing accurate patient data for analysis of results. 5. Providing skilled medical professionals to plan, conduct, and evaluate the studies. 6. Developing and testing new ideas with local research projects. 7. Administering and conducting these studies efficiently at the lowest cost. This research is conducted at the Children's Hospital of Pittsburgh (CHP), a 235 bed not for profit hospital which is the pediatric referral center for a population of 4 to 5 million people. CHP is associated with the University of Pittsburgh School of Medicine and serves as its Department of Pediatrics. CHP is also a full member of the Pittsburgh Cancer Institute, an NIH designated comprehensive cancer center and has been a member of CCG since 1961. During the Past year, a completely renovated, dedicated oncology ward and a new CCG approved bone marrow transplant (BMT) program have been opened to improve our ability to conduct research. Our multi-disciplinary pediatric oncology/BMT team has expanded to 10 oncologists and includes surgeons (including neuro and orthopedic), radiation oncologists, diagnostic radiologists, pediatric pathologists, a hematopathologist, cytogeneticists, a neurologist, epidemiologists, cardiologists, psychologists, and a complete support team (nursing, data managers, social service, a specimen coordinator, etc.). With the opening of the new CHP Rangos Research Building and the establishment of three new faculty members with independent funding, we have increased our laboratory research and anticipate an increase in basic research contributions to CCG. With a larger number of investigators, we also anticipate maximum participation in CCG. We expect to increase patient enrollment in therapeutic, biologic, and epidemiologic studies. There were 139 patients entered on study during 1992 (therapeutic, special, and epidemiologic) and we anticipate even a higher on-study number m the coming years since we have been approved as a phase I and BMT center in the past year. We are also planning to take a larger scientific and administrative role in CCG with the recent expansion in our staff. In addition, we have local independent cancer research projects in progress that we hope will benefit our patients and CCG. These non-CCG clinical and laboratory cancer projects include but are not limited to: The proliferative response of acute leukemia cells to recombinant growth factor; neuroblastoma treatment with deferoxamine; delineating mechanisms of signal transduction mediated via GM-CSF on CD4; the study of signal transduction by proto-oncogenes including the anti-proliferative effects of anti-sense molecules.